Literature DB >> 18481222

Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

V Durmanová1, M Sapák, J Kosovský, I Rezuchová, M Kúdelová, M Buc, J Rajcáni.   

Abstract

Balb/c mice were immunized with the recombinant fusion protein gD1/313 (FpgD1/313 representing the ectodomain of HSV-1 gD), with the non-pathogenic ANGpath gE-del virus, with the plasmid pcDNA3.1-gD expressing full-length gD1 and with the recombinant immediate early (IE) HSV-1 protein ICP27. Specific antibodies against these antigens (as detected by ELISA) reached high titers with the exception of the DNA vaccine. High-grade protection against challenge with the virulent strain SC16 was found following immunization with the pcDNA3.1-gD plasmid and with the gE-del virus. Medium grade, but satisfactory protection developed after immunization with the FpgD1/313 and minimum grade protection was seen upon immunization with the IE/ICP27 polypeptide. A considerable response of peripheral blood cells (PBL) and splenocytes in the lymphocyte transformation test (LTT) was found in mice immunized with FpgD1/313, with the pcDNA3.1-gD plasmid and with the live ANGpathgE-del virus. For lymphocyte stimulation in vitro, the FpgD1/313 antigen was less effective than the purified gD1/313 polypeptide (cleaved off from the fusion protein); both proteins elicited higher proliferation at the 5 microg per 0.1 mL dose than at the 1 microg per 0.1 mL dose. The secretion of Th type 1 (TNF, IFN-gamma and IL-2) and Th type 2 (IL-4 and IL-6) cytokines was tested in the medium fluid of purified PBL and splenocyte cultures; their absolute values were expressed in relative indexes. The PBL from FpgD1/313 immunized mice showed increased secretion of both T(H)1 (TNF) as well as T(H)2 (IL-4) cytokines (7-10-fold, respectively). Splenocytes from FpgD1/313 immunized mice showed a significant (23-fold) increase in IL-4 production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481222     DOI: 10.1007/s12223-008-0011-4

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.629


  64 in total

1.  Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses.

Authors:  T J Higgins; K M Herold; R L Arnold; S P McElhiney; K E Shroff; C J Pachuk
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

2.  Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry.

Authors:  J C Whitbeck; C Peng; H Lou; R Xu; S H Willis; M Ponce de Leon; T Peng; A V Nicola; R I Montgomery; M S Warner; A M Soulika; L A Spruce; W T Moore; J D Lambris; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Expression of herpes simplex virus 1 glycoprotein D in prokaryotic and eukaryotic cells.

Authors:  T Mosko; J Kosovský; I Rezuchová; V Durmanová; M Kúdelová; J Rajcáni
Journal:  Acta Virol       Date:  2004       Impact factor: 1.162

4.  Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.

Authors:  E M Mishkin; J R Fahey; Y Kino; R J Klein; A S Abramovitz; S J Mento
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

5.  An analysis of the biological properties of monoclonal antibodies against glycoprotein D of herpes simplex virus and identification of amino acid substitutions that confer resistance to neutralization.

Authors:  A C Minson; T C Hodgman; P Digard; D C Hancock; S E Bell; E A Buckmaster
Journal:  J Gen Virol       Date:  1986-06       Impact factor: 3.891

6.  Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1.

Authors:  W P Halford; B M Gebhardt; D J Carr
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

7.  DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

Authors:  N Bourne; G N Milligan; M R Schleiss; D I Bernstein; L R Stanberry
Journal:  Vaccine       Date:  1996-09       Impact factor: 3.641

8.  Immunological memory to herpes simplex virus type 1 glycoproteins B and D in mice.

Authors:  B A Blacklaws; A A Nash
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

9.  A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

Authors:  M Singh; J R Carlson; M Briones; M Ugozzoli; J Kazzaz; J Barackman; G Ott; D O'Hagan
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

10.  IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis.

Authors:  Eeva K Broberg; Aimo A Salmi; Veijo Hukkanen
Journal:  Neurosci Lett       Date:  2004-07-08       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.